{
    "eid": "2-s2.0-84962651870",
    "title": "Patient management with eribulin in metastatic breast cancer: A clinical practice guide",
    "cover-date": "2016-03-01",
    "subject-areas": [
        {
            "$": "Cancer Research",
            "@code": "1306"
        },
        {
            "$": "Oncology",
            "@code": "2730"
        }
    ],
    "keywords": [
        "Asians",
        "Breast neoplasms",
        "Chemotherapy",
        "Eribulin mesylate"
    ],
    "authors": [
        "Jungsil Ro"
    ],
    "citedby-count": 11,
    "ref-count": 62,
    "ref-list": [
        "Is Breast Cancer Survival Improving? Trends in Survival for Patients with Recurrent Breast Cancer Diagnosed from 1974 through 2000",
        "Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer",
        "The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer",
        "Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up",
        "Considerations in treatment choice for metastatic breast cancer",
        "In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B",
        "The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth",
        "Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase",
        "Eribulin induces irreversible mitotic blockade: Implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions",
        "Cancer Res",
        "Cancer Res",
        "Cancer Res",
        "A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies",
        "Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors",
        "Eribulin: Summary of Product Characteristics",
        "Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase i trial in patients with advanced solid tumors: A California Cancer Consortium trial",
        "Eribulin mesylate in patients with refractory cancers: A Phase i study",
        "Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine",
        "Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane",
        "A phase II study of eribulin in Japanese patients with: Heavily pretreated metastatic breast cancer",
        "Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study",
        "Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane",
        "Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies",
        "Ann Oncol",
        "Cancer Res",
        "Eur J Cancer",
        "Cancer Res",
        "J Clin Oncol",
        "NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Version 3",
        "Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American society of clinical oncology clinical practice guideline",
        "ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)",
        "American society of clinical oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes",
        "Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer",
        "Cancer Res",
        "Risk models for predicting chemotherapy-induced neutropenia",
        "2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours",
        "NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors Version 2",
        "Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications",
        "Peripheral neuropathy induced by microtubule-stabilizing agents",
        "Peripheral neuropathy with microtubule-targeting agents: Occurrence and management approach",
        "J Clin Oncol",
        "Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: Use of a \"physician's choice\" control arm in a randomized approval trial",
        "Chemotherapy-evoked painful peripheral neuropathy",
        "Chemotherapy-induced peripheral neuropathy",
        "Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy",
        "Peripheral Neuropathy Related to Chemotherapy",
        "A review on oxaliplatin-induced peripheral nerve damage",
        "Chemotherapy-induced peripheral neuropathy",
        "Greater risks of chemotherapy toxicity in elderly patients with cancer.",
        "Neurotoxicity of cancer chemotherapy",
        "Neurologic complications of chemotherapy agents",
        "Platinum neurotoxicity pharmacogenetics",
        "Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer",
        "The chemotherapy-induced peripheral neuropathy outcome measures standardization study: From consensus to the first validity and reliability findings",
        "NCCN task force report: Management of neuropathy in cancer",
        "Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline",
        "Chemotherapy-Induced Alopecia",
        "NCCN Clinical Practice Guidelines in Oncology: Antiemesis Version 2",
        "Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference",
        "Antiemetics: American Society of Clinical Oncology clinical practice guideline update",
        "Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment",
        "Cancer Res"
    ],
    "affiliation": [
        {
            "affiliation-city": "Goyang",
            "affilname": "National Cancer Center, Gyeonggi",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Singapore City",
            "affilname": "National Cancer Centre, Singapore",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Taipei",
            "affilname": "Shin Kong Wu Ho-Su Memorial Hospital",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Mumbai",
            "affilname": "Bombay Hospital and Medical Research Centre",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Hong Kong",
            "affilname": "The University of Hong Kong",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Manila",
            "affilname": "Manila Doctor's Hospital",
            "affiliation-country": "Philippines"
        }
    ],
    "funding": []
}